Lupin receives UFDA approval for Gatifloxacin ophthalmic solution

30 Aug 2013 Evaluate

Lupin has received United States Food and Drugs Administration (UFDA)’s approval for Gatifloxacin 0.5% ophthalmic solution. Gatifloxacin, a broad-spectrum antibiotic, is formulated as eye drops for ophthalmic use. It is indicated for the treatment of bacterial conjunctivitis and keratitis (including corneal ulcer) and is a fluoroquinoline antibacterial antibiotic that acts by inhibiting bacterial topoisomerases II and IV, enzymes which are essential for bacterial DNA replication, transcription and translation. Earlier, in July the company received FDA tentative approval for Gatifloxacin ophthalmic solution.

Recently, Lupin’s - US subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has received final approval for its Rifampin Capsules USP, 150 mg and 300 mg strengths from the United States Food and Drugs Administration (USFDA).

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.

Lupin Share Price

2097.65 5.70 (0.27%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×